Extended endocrine therapy in early breast cancer: how long and who for?

Benson, John R. and Jatoi, Ismail (2020) Extended endocrine therapy in early breast cancer: how long and who for? Future Oncology, 16 (1). pp. 4327-4336. ISSN 1744-8301

[img]
Preview
Text
Accepted Version
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (667kB) | Preview
Official URL: https://doi.org/10.2217/fon-2019-0254

Abstract

Endocrine therapy for early stage breast cancer is currently in a state of flux with much uncertainty about choice of agents and duration of therapy. The standard treatment span of 5 years usually incorporates an aromatase inhibitor in the majority of postmenopausal patients. Hormonal therapy has a cytostatic action that provides a biological rationale for continuing treatment for more prolonged periods to reduce risk of late recurrence in estrogen receptor-positive disease. Several trials of extended endocrine therapy for periods varying from 7.5 to 10 years have shown mixed results for gains in disease-free survival. The challenge is to assimilate available data and apply clinical judgment to tailor therapies taking account of intrinsic risk of disease recurrence, patient preference, tolerability to date, and co-morbidities.

Item Type: Journal Article
Keywords: aromatase inhibitor, breast cancer, endocrine, extended
Faculty: Faculty of Health, Education, Medicine & Social Care
Depositing User: Lisa Blanshard
Date Deposited: 24 Apr 2020 14:04
Last Modified: 20 Jan 2021 11:35
URI: https://arro.anglia.ac.uk/id/eprint/705442

Actions (login required)

Edit Item Edit Item